April 20, 2026
An End to Subjective RPR Reading? Development of a Novel Automated Nontreponemal Immunoassay for Syphilis
Syphilis remains a growing global public health challenge, with an estimated 8 million new cases reported in 2022. Congenital syphilis continues to rise as well, underscoring the urgent need for faster, more reliable diagnostic solutions.
Traditional nontreponemal tests such as RPR rely on manual workflows and visual interpretation—introducing subjectivity, variability, and delays in patient care.
ALPCO is advancing syphilis diagnostics with a novel fully automated nontreponemal immunoassay designed to modernize active infection testing and streamline laboratory workflows.
Want the full data? Download the complete poster abstract to explore the findings in detail.